SCHEDULE: Morgan Stanley Discloses 6.3% Stake in AnaptysBio

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have disclosed a combined beneficial ownership of 6.3% in AnaptysBio, Inc. common stock.

Summary

• Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have filed a Schedule 13G disclosing their beneficial ownership in AnaptysBio, Inc.
• Morgan Stanley beneficially owns an aggregate of 1,845,002 shares of AnaptysBio, Inc. common stock, representing 6.3% of the class.
• Morgan Stanley Capital Services LLC, a wholly-owned subsidiary of Morgan Stanley, beneficially owns 1,525,502 shares, representing 5.2% of the class.
• The shares are held in the ordinary course of business and not for the purpose of changing or influencing control of AnaptysBio, Inc.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of passive beneficial ownership by a large institutional investor, indicating a neutral sentiment as it does not convey positive or negative operational news or strategic intent beyond ordinary course investment.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• NA

Industry Context

This filing reflects a passive investment by a major financial institution in AnaptysBio, Inc., a biotechnology company. Such disclosures are routine for institutional investors crossing significant ownership thresholds and do not typically indicate strategic shifts or direct industry trends beyond general market interest in the sector.

Comparison to Industry Standards

• NA

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• This filing primarily impacts shareholders by providing transparency on significant institutional ownership. It indicates that a major financial institution holds a substantial, albeit passive, stake in the company. There is no direct impact on employees, customers, suppliers, or creditors mentioned.

Next Steps

• NA

Key Dates

Recommendation

This Schedule 13G filing indicates a passive ownership stake by Morgan Stanley and its subsidiary in AnaptysBio, Inc. It does not provide any new financial or operational information about AnaptysBio that would warrant a change in investment recommendation. The disclosure is routine for institutional investors and explicitly states the holding is for ordinary course business, not for control. Therefore, a 'hold' recommendation is appropriate as the filing itself does not present a catalyst for a 'buy' or 'sell' decision.

Keywords

AnaptysBio, Morgan Stanley, Schedule 13G, Common Stock, Beneficial Ownership, Institutional Investor, SEC Filing, Biotechnology